SCHEMBL20135181

SCHEMBL20135181

Cc1cnc(N2CCN(C(=O)c3ccc(C4(C5CC5)NC(=O)NC4=O)cc3)CC2)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADAMTS5 Q9UNA0 8/20 0.40
ADAM17 P78536 4/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 2/20 0.38
MMP2 P08253 2/20 0.37
ADAMTS4 O75173 1/20 0.37
MMP1 P03956 1/20 0.37
MMP12 P39900 1/20 0.37
POLB P06746 1/20 0.36
HTT P42858 1/20 0.36
SLC6A7 Q99884 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MMP14 P50281 1/20 0.36
MAPK1 P28482 1/20 0.35
MMP9 P14780 1/20 0.35
GBA1 P04062 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688749 1.00 ADAMTS5 (0.40) ADAMTS5ADAM17ALDH1A1KDM4EMMP2
SCHEMBL29688916 0.96 ALDH1A1 (0.38) ADAMTS5ADAM17ALDH1A1KDM4EMMP2
SCHEMBL20135135 0.96 ALDH1A1 (0.38) ADAMTS5ADAM17ALDH1A1KDM4EMMP2
SCHEMBL29688853 0.94 ADAM17 (0.37) ADAMTS5ADAM17ALDH1A1KDM4EPOLB
SCHEMBL20135058 0.94 ADAM17 (0.37) ADAMTS5ADAM17ALDH1A1KDM4EPOLB
SCHEMBL20135138 0.90 SLC6A7 (0.37) ADAMTS5ADAM17ALDH1A1KDM4EMMP2
SCHEMBL29688969 0.90 SLC6A7 (0.37) ADAMTS5ADAM17ALDH1A1KDM4EMMP2
SCHEMBL20134916 0.87 SLC6A7 (0.38) ADAMTS5ADAM17ALDH1A1KDM4EMMP2
SCHEMBL20135262 0.87 HTT (0.39) ADAMTS5ADAM17KDM4EMMP2ADAMTS4
SCHEMBL29688813 0.87 SLC6A7 (0.38) ADAMTS5ADAM17ALDH1A1KDM4EMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 ADAMTS5 23/4885ADAM17 36/4885ALDH1A1 584/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 ADAMTS5 25/4885ADAM17 39/4885ALDH1A1 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.